Asylia Therapeutics is a private development stage biotechnology company committed to transforming scientific advances into safe and effective medicines for cancer, autoimmune and infectious diseases. Founded in 2019 and based in Houston, Texas, the company is led by a seasoned team of entrepreneurs, scientific leaders in immunity, oncology and clinical trials, and biotech executives with experience in antibody drug and business development.